### Potential Cancer Risk Reduction with Ozempic and Wegovy Ozempic and Wegovy are drugs primarily used to treat diabetes and obesity. Recent research suggests that these medications might also help reduce cancer risk. A small study published in the journal Obesity found that semaglutide, the active ingredient in both drugs, can improve the function of natural killer cells. These cells are crucial in fighting cancer but often don't work properly in people with obesity. The study involved 20 participants with obesity who had impaired natural killer cell function. They received weekly doses of semaglutide for six months. The results showed significant improvement in the function of these cells, regardless of the amount of weight lost. This indicates that semaglutide might offer benefits beyond weight loss. Previous research on the link between GLP-1 drugs (the class of drugs to which semaglutide belongs) and cancer risk has shown mixed results. Some studies suggest a reduced risk of cancer, while others indicate a potential increase in certain types of cancer, such as thyroid, pancreatic, and breast cancer. The latest study is too small to draw broad conclusions, but it provides a plausible explanation for how semaglutide might reduce cancer risk. Excess fat tissue can lead to inflammation, trapping natural killer cells and reducing their ability to fight cancer. Semaglutide may have anti-inflammatory properties that free these trapped cells, allowing them to function properly again. While more extensive research is needed, these findings offer hope that Ozempic and Wegovy could provide additional health benefits beyond their primary uses.